Trial Profile
Early access of MK0518 [raltegravir] in combination with an optimized background antiretroviral therapy (OBT) in highly treatment experienced HIV-1 infected patients with limited to no treatment options
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Expanded access; Therapeutic Use
- Acronyms EARMRK
- Sponsors Merck & Co; Merck Sharp & Dohme
- 11 May 2007 New trial record.